Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

BioLight Approved to Market Glaucoma Medical Device in China

publication date: Mar 7, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
BioLight Israeli Life Sciences Investments reported that a subsidiary, IOPtima, received CFDA approval for China marketing of the IOPtiMate™ system. IOPtiMate is a non-invasive surgical device that treats glaucoma. BioLight also completed a secondary offering, raising $5.5 million, which is will use, in part, to promote IOPtiMate in China. More details....

Stock Symbol: (TASE: BOLT; OTCQX: BLGTY)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...